Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Reports on “Comprehensive Strategy” at Chuikyo
September 10, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 2
September 10, 2015
- Drug Pricing Tomorrow: MOF Budget Examiner Eyes “Sharp Price Cuts” for Both New and Listed Generics in 2016
September 9, 2015
- MHLW Launches Office to Promote Genomic Medicine
September 9, 2015
- Drug Pricing Tomorrow: Full Interview with MHLW Councilor Takeda - Part 1
September 9, 2015
- Research-Driven Makers Need Enough Capital Strength to Withstand Discontinuation of R&D Projects: Comprehensive Strategy
September 8, 2015
- Can’t Give Timeline for Active Recommendation for HPV Vaccines, Expert Discussions Eyed: Govt
September 8, 2015
- Notification Service for Generic Use Saves 15.8 Billion Yen in Medical Spending in FY2014: Kyokai Kenpo
September 8, 2015
- MHLW Announces Comprehensive Strategy to Beef Up Pharma Industry, Vows to Promote Reward for Innovation
September 7, 2015
- Japan Medical Spending Hits Another Record in FY2014, Year-End Generic Share at 58.4%: MHLW
September 7, 2015
- MEXT Funding Research Project to Propose New Business Models and Financing Methods to Promote Drug Development
September 4, 2015
- PAFSC Committee Recommends Approval for 2 Regenerative Medicine Products
September 4, 2015
- PMDA to Select Products for Sakigake Review; “Probably 5 to 10” Will Be Designated: Official
September 3, 2015
- 5 Companies Find 46 Unreported ADR Cases as a Result of Self-Inspections
September 3, 2015
- Ryukaikon Calls for Elimination of Medical Fee Cut Rule for Low Price Settlement Rates Once Early Price Settlements Are Achieved
September 2, 2015
- Ryukaikon Submits New Proposal to Improve Drug Distribution Environment
September 2, 2015
- AbbVie’s Hep C Drug OK’ed by PAFSC Committee, Setting Stage for Competition with Harvoni
September 1, 2015
- PAFSC First Committee Backs Approval of Glatiramer, Add’l Indication for Xarelto
August 31, 2015
- FY2016 Budget Request to Earmark 151.5 Billion Yen for AMED, with 25.3 Billion Yen for Drug Discovery and Development
August 31, 2015
- METI Seeks 126.9 Billion Yen in FY2016 Budget for Science, Technology Promotion, 21.2 Billion Yen for AMED
August 31, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…